A boxed warning has been added to the label for Metformin Hydrochloride, effective 2026-06-08. This warning specifically addresses the risk of lactic acidosis. The label states: "WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin associated lactic acidosis is often subtle."
What this means
The addition of a boxed warning for lactic acidosis to the Metformin Hydrochloride label is a significant update for healthcare professionals. This warning explicitly details the severe consequences observed in postmarketing cases, including death, hypothermia, hypotension, and resistant bradyarrhythmias. The emphasis on the subtle onset of metformin-associated lactic acidosis underscores the challenge in early detection and the need for heightened clinical vigilance. This label revision aims to ensure that clinicians are fully informed about the potential for this serious adverse event, prompting careful consideration of patient risk factors, thorough patient education, and proactive monitoring to facilitate timely intervention and improve patient safety outcomes when prescribing or managing patients on Metformin Hydrochloride.
Source
This information regarding the boxed warning for Metformin Hydrochloride was obtained from the FDA, as documented in a label revision effective 2026-06-08. The details are available on dailymed.nlm.nih.gov.